Risk factors

Actuate Therapeutics (ACTU) risk factors

Item 1A of every Actuate Therapeutics, Inc. 10-K on file, and what changed from one year to the next.

Open ACTU in Gloomberb →
  • FY2025 10-K risk factors

    45 risks, 3 new, 41 dropped, 19 reworded since the prior year. Actuate Therapeutics discloses cash runway only extending to July 2026 for its sole drug candidate, elraglusib. Reliance on a single drug substance manufacturer in China creates geopolitical supply chain risks.

    Filed Mar 26, 2026
  • FY2024 10-K risk factors

    83 risks. Actuate Therapeutics has a limited operating history with no commercial products and faces going concern risks with only $8.6 million in cash.

    Filed Mar 13, 2025